A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.

Janjigian, Yelena Y.; Ku, Geoffrey Yuyat; Ilson, David H.; Boyar, Michelle S.; Capanu, Marinela; Chou, Joanne F.; Kelsen, David P.; Imtiaz, Tooba; Berger, Michael F.; Vakiani, Efsevia

doi:10.1200/jco.2015.33.3_suppl.59

Cited by 24 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, an ongoing Phase II trial is assessing the combination in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer (NCT01522768 ; Table 1); preliminary data from this trial indicated that afatinib monotherapy was well tolerated and showed clinical activity in this setting [89]; the addition of trastuzumab to afatinib was mandated in a protocol amendment.…”

Section: Afatinib Plus Her2 Antibodiesmentioning

confidence: 98%

Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress

Bennouna

Vera

2015

Future Oncol.

View full text Add to dashboard Cite

In oncology, there is a clinical need for novel combination therapy regimens that maximize efficacy and delay resistance to individual treatment modalities. Given the role of aberrant ErbB receptor signaling in the pathogenesis of many human cancers, there is rationale for incorporating afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor, into such combinations. This review focuses on: pharmacological properties of afatinib that facilitate its use in combination; preclinical rationale for the combination of afatinib with other agents; and recently completed, and ongoing, clinical trials of afatinib-based combinations across tumor types. Based on these data, we emphasize a number of areas of high unmet medical need that could benefit from afatinib-based combinations, including patients with relapsed/refractory non-small-cell lung cancer.

show abstract

Section: Afatinib Plus Her2 Antibodiesmentioning

confidence: 98%

Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress

Bennouna

Vera

2015

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…Preliminary data of a phase II study enrolling patients with metastatic HER2-positive (IHC 3+ or FISH >2.0) esophagogastric cancer with disease progression whilst on a trastuzumab-containing regimen have been recently presented [53, 54] with demonstration of a 40% disease control.…”

Section: Her-2 As a Key Target In Gastric Cancers And Gastroesophageamentioning

confidence: 99%

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

et al. 2016

View full text Add to dashboard Cite

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

show abstract

“…Afatinib, a multi-kinase inhibitor of EGFR, HER2 and HER4, showed signal in a phase II study involving patients with trastuzumab refractory disease 50. An expansion cohort looking at safety and efficacy in combination with trastuzumab is currently recruiting (NCT01522768).…”

Section: Future Directions In Her2 Targetingmentioning

confidence: 99%

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

Davidson¹,

Starling²

2016

OTT

View full text Add to dashboard Cite

The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.

show abstract

A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.

Cited by 24 publications

References 0 publications

Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress

Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

Contact Info

Product

Resources

About